Table 2.
Cell cycle analysis of fullerene derivatives U937 treated cells.
| % G1 | % S | % G2M | |
|---|---|---|---|
| 24 h | |||
| Control | 36.3 ± 0.7 | 59.9 ± 0.9 | 3.9 ± 0.2 |
| Fullerene 1 | 35.7 ± 0.5 | 58.3 ± 0.3 | 6.0 ± 0.4∗∗∗ |
| Fullerene 2 | 37.0 ± 0.8 | 56.6 ± 0.8∗ | 6.4 ± 0.2∗∗∗ |
| 48 h | |||
| Control | 46.2 ± 1.7 | 47.6 ± 1.3 | 6.2 ± 0.5 |
| Fullerene 1 | 43.1 ± 0.7 | 50.6 ± 0.5∗ | 6.3 ± 0.7 |
| Fullerene 2 | 37.9 ± 0.8∗∗,§ | 55.0 ± 0.3∗∗∗,§§ | 7.1 ± 0.5 |
| 72 h | |||
| Control | 46.7 ± 0.7 | 47.5 ± 0.5 | 5.8 ± 0.5 |
| Fullerene 1 | 46.4 ± 0.8 | 47.7 ± 0.6 | 5.9 ± 0.3 |
| Fullerene 2 | 43.2 ± 0.6∗,§ | 50.7 ± 0.4∗∗,§§ | 6.0 ± 0.3 |
Cells (1 × 106/mL) were exposed for 24–72 hr long-lasting treatment with 10 μM of fullerene 1 and fullerene 2 and then subjected to PI staining prior to performing the flow cytometric cell cycle analysis. The percentage of each phase reported was calculated by MCycle analysis software. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001 versus untreated controls; § P < 0.05, §§ P < 0.01 versus fullerene 1; Student-Newman-Keuls multiple comparisons test, ANOVA.